Polyneuropathy

Polyneuropathy (poly- + neuro- + -pathy) is damage or disease affecting peripheral nerves (peripheral neuropathy) in roughly the same areas on both sides of the body, featuring weakness, numbness, and burning pain. It usually begins in the hands and feet and may progress to the arms and legs and sometimes to other parts of the body where it may affect the autonomic nervous system. It may be acute or chronic. A number of different disorders may cause polyneuropathy, including diabetes and some types of Guillain–Barré syndrome.

Classification

Polyneuropathies may be classified in different ways, such as by cause, by presentation, or by classes of polyneuropathy, in terms of which part of the nerve cell is affected mainly: the axon, the myelin sheath, or the cell body.

Action potential propagation in myelinated neurons is faster than in unmyelinated neurons(left)

• Distal axonopathy, is the result of interrupted function of the peripheral nerves. It is the most common response of neurons to metabolic or toxic disturbances, and may be caused by metabolic diseases such as diabetes, kidney failure, connective tissue disease, deficiency syndromes such as malnutrition and alcoholism, or the effects of toxins or drugs such as chemotherapy. They may be divided according to the type of axon affected (large-fiber, small-fiber, or both), the most distal portions of axons are usually the first to degenerate, and axonal atrophy advances slowly toward the nerve's cell body. However, if the cause is removed, then regeneration is possible, although the prognosis depends on the duration and severity of the original stimulus. People with distal axonopathies usually present with sensorimotor disturbances such as amyotrophic lateral sclerosis
• Myelinopathy, is due to a loss of myelin or of the Schwann cells. This demyelination slows down or completely blocks the conduction of action potentials through the axon of the nerve cell (neurapraxia). The most common cause is acute inflammatory demyelinating polyneuropathy AIDP, the most common form of Guillain–Barré syndrome (although other causes include chronic inflammatory demyelinating polyneuropathy )
• Neuronopathy is the result of issues in the peripheral nervous system (PNS) neurons. They may be caused by motor neurone diseases, sensory neuronopathies, toxins, or autonomic dysfunction. Neurotoxins such as chemotherapy agents may cause neuronopathies.

Signs and symptoms

Among the signs/symptoms of polyneuropathy, which can be divided (into sensory and hereditary) and are consistent with the following:

• Sensory polyneuropathy – ataxia, numbness, muscle wasting and paraesthesiae.
• Hereditary polyneuropathy – scoliosis and hammer toes

Causes

The causes of polyneuropathy can be divided into hereditary and acquired and are therefore as follows:

• Inherited -are hereditary motor neuropathies, Charcot–Marie–Tooth disease, and hereditary neuropathy with liability to pressure palsy
• Acquired -are diabetes mellitus, vascular neuropathy, alcohol abuse, and vitamin B12 deficiency

Pathophysiology

6/62/Healthy_Human_T_Cell.jpg/100px-Healthy_Human_T_Cell.jpg" decoding="async" width="100" height="100" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/62/Healthy_Human_T_Cell.jpg/150px-Healthy_Human_T_Cell.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/62/Healthy_Human_T_Cell.jpg/200px-Healthy_Human_T_Cell.jpg 2x" data-file-width="1884" data-file-height="1884">

Human T Cell

In regard to the pathophysiology of polyneuropathy, of course, the former depends on which polyneuropathy. For instance in the case of chronic inflammatory demyelinating polyneuropathy, one finds that it is an autoimmune disease. Here, T cells involvement has been demonstrated, while in terms of demyelination, antibodies alone are not capable.

Diagnosis

6/61/Ragged_red_fibres_-_gtc_-_very_high_mag.jpg/170px-Ragged_red_fibres_-_gtc_-_very_high_mag.jpg" decoding="async" width="170" height="113" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/61/Ragged_red_fibres_-_gtc_-_very_high_mag.jpg/255px-Ragged_red_fibres_-_gtc_-_very_high_mag.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/61/Ragged_red_fibres_-_gtc_-_very_high_mag.jpg/340px-Ragged_red_fibres_-_gtc_-_very_high_mag.jpg 2x" data-file-width="3642" data-file-height="2428">

Micrograph of a muscle biopsy

The diagnosis of polyneuropathies begins with a history and physical examination to ascertain the pattern of the disease process (such as-arms, legs, distal, proximal) if they fluctuate, and what deficits and pain are involved. If pain is a factor, determining where and how long the pain has been present is important, one also needs to know what disorders are present within the family and what diseases the person may have. Although diseases often are suggested by the physical examination and history alone, tests that may be employed include: electrodiagnostic testing, serum protein electrophoresis, nerve conduction studies, urinalysis, serum creatine kinase (CK) and antibody testing (nerve biopsy is sometimes done).

Other tests may be used, especially tests for specific disorders associated with polyneuropathies, quality measures have been developed to diagnose patients with distal symmetrical polyneuropathy (DSP).

Differential diagnosis

In terms of the differential diagnosis for polyneuropathy one must look at the following:

Treatment

Methylprednisolone

In the treatment of polyneuropathies one must ascertain and manage the cause, among management activities are: weight decrease, use of a walking aid, and occupational therapist assistance. Additionally, BP control in those with diabetes is helpful, while intravenous immunoglobulin is used for multifocal motor neuropathy.

According to Lopate, et al., methylprednisolone is a viable treatment for chronic inflammatory demyelinative polyneuropathy (which can also be treated with intravenous immunoglobulin). The authors also indicate that prednisone has greater adverse effects in such treatment, as opposed to intermittent (high-doses) of the aforementioned medication.

According to Wu, et al., in critical illness polyneuropathy supportive and preventive therapy are important for the affected individual, as well as, avoiding (or limiting) corticosteroids.

See also